Literature DB >> 2849656

Alpha-1 adrenergic receptors in the nonfailing and failing human heart.

M R Bristow1, W Minobe, R Rasmussen, R E Hershberger, B B Hoffman.   

Abstract

We examined alpha-1 adrenergic receptor density in ventricular myocardium from nonfailing and failing human hearts, utilizing the alpha-1 radioligand [125I]IBE2254. The alpha-1 receptor population comprised a relatively small portion of the total adrenergic receptors, 14.6 +/- 1.9%. However, in failing human ventricular myocardium the alpha-1 adrenergic receptor population constituted a much greater portion, 27.3 +/- 2.1% (P less than .01). The reason for the increased proportion of alpha-1 adrenergic receptors was not that the total concentration of alpha-1 receptors was increased, but instead was due to selective down-regulation of the beta-1 adrenergic receptor population. Beta-2 adrenergic receptors behaved similarly to alpha-1 adrenergic receptors in the failing human heart, and were increased in proportion and unchanged in total number. Additionally, the ability of alpha-1 stimulation to increase the incorporation of label from [3H]inositol into inositol phosphates was examined in tissue homogenates. Maximal doses of norepinephrine produced only marginal stimulation of phosphatidylinositol hydrolysis, in contrast to a more substantial response produced by muscarinic stimulation. We conclude that human ventricular myocardium contains alpha-1 adrenergic receptors that 1) are of relatively low density, 2) are unchanged in density by heart failure and 3) mediate relatively low-level stimulation of phosphatidylinositol hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849656

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

Review 1.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 2.  Cardiac GPCRs: GPCR signaling in healthy and failing hearts.

Authors:  Natasha C Salazar; Juhsien Chen; Howard A Rockman
Journal:  Biochim Biophys Acta       Date:  2007-02-20

Review 3.  Inotropic agents for heart failure: what if digoxin increases mortality?

Authors:  W J Remme
Journal:  Br Heart J       Date:  1994-09

Review 4.  Adrenergic control of cardiac gap junction function and expression.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-12       Impact factor: 3.000

5.  Phentolamine and hypoxia: modulation of contractility and alpha 1-adrenoceptors in isolated rat atria.

Authors:  G Froldi; L Guerra; L Pandolfo; A Chinellato; E Ragazzi; L Caparrotta; P A Borea; G Fassina
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

6.  Novel proteins associated with human dilated cardiomyopathy: selective reduction in α(1A)-adrenergic receptors and increased desensitization proteins.

Authors:  Ting Shi; Christine S Moravec; Dianne M Perez
Journal:  J Recept Signal Transduct Res       Date:  2013-02-06       Impact factor: 2.092

7.  Altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog.

Authors:  K Li; J L Rouleau
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

8.  Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.

Authors:  M R Bristow; P Larrabee; B Müller-Beckmann; W Minobe; R Roden; L Skerl; J Klein; D Handwerger; J D Port
Journal:  Clin Investig       Date:  1992

9.  Cardiac alpha 1-adrenoceptor densities in different mammalian species.

Authors:  M Steinfath; Y Y Chen; J Lavický; O Magnussen; M Nose; S Rosswag; W Schmitz; H Scholz
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

Review 10.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.